Primrose Bio, Inc. (“Primrose”), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by new investor Signet Healthcare Partners (“Signet”), with significant participation from existing investors 1315... $2 million grant builds on research to develop sequence elements that improve DNA- and RNA-based medicine efficacy Primrose Bio, Inc., a company with proprietary biologic manufacturing technologies, today announced a $2 million, 24-month Direct-to-Phase II Small... The companies will leverage their combined experience in the development of conjugate vaccines for their clients Primrose Bio will supply its industry-leading carrier protein, PeliCRM197®, for vaccine development Intravacc has know-how in vaccine conjugation and... Novel approach to engineering complex microbial traits generates tens of millions of gene combinations, enabling gain-of-function traits beyond those observed from individual genes San Diego, Calif. April 8, 2026 – Primrose Bio, Inc. (Primrose), a company with... Maximize capping efficiency and minimize double-stranded RNA (“dsRNA”) in the manufacturing of self-amplifying mRNA San Diego, Calif. Nov. 10, 2025 – Primrose Bio, Inc. (“Primrose”), a company with proprietary therapeutic manufacturing technologies, today announced... San Diego, Calif. October 1, 2025 – Primrose Bio, Inc. (“Primrose”) announced today the appointment of Andrew “Drew” Burch as its Chief Executive Officer, and member of the Board of Directors. Drew succeeds Helge Zieler, PhD, who will move into a new role of Chief... Significantly increased quality and lower manufacturing costs for long template mRNAs San Diego, Calif. March 26, 2025 – Primrose Bio, Inc. (“Primrose”), a company developing proprietary therapeutic manufacturing technologies, announces the launch of Prima RNApols™... Primrose Bio, Inc. (“Primrose”), a company with proprietary manufacturing technologies for human therapeutics, and Serum Institute of India Pvt. Ltd. (“SIIPL”), the world’s largest vaccine manufacturer, today announced a collaboration to develop a novel multi-antigen... Primrose Bio, a leading biotechnology company specializing in technologies that improve the manufacturing of next-generation therapeutics, and ExPLoRNA Therapeutics, a pioneering biotechnology company advancing mRNA technologies, vaccines, and therapeutics, announced... Primrose Bio, Inc. (“Primrose,” the “Company”), a company focused on developing and licensing its manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines, announced a significant equity investment from 1315 Capital, a... Primrose Bio Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
Primrose Bio Awarded NIH Grant to Develop Genetic Medicine Drug Design Technology
Intravacc and Primrose Bio Renew Partnership to Enhance Conjugate Vaccine Development
Primrose Bio Function Generator™ Combinatorial Genetic Technology Case Study Published in PNAS
Primrose Bio Launches Prima RNApols™ ExTend Cap AU, a Next-Gen RNA Polymerase for Self-Amplifying mRNA
Primrose Bio Names Drew Burch as CEO
Primrose Bio Launches Prima RNApols™ ExTend, an RNA Polymerase for Long-Template mRNA Manufacturing
Primrose Bio to Collaborate with Serum Institute of India to Develop a Novel Multi-Antigen Vaccine
Primrose Bio and ExPLoRNA Therapeutics Announce Strategic Partnership to Advance mRNA Medicines
Primrose Bio Announces Investment from 1315 Capital to Advance Manufacturing Solutions for Next-Generation Therapeutics
Most biologics teams do not begin development by choosing an expression host from a blank slate. A number of factors contribute to delivering a robust, highly productive, and reliable process for manufacturing a therapeutic protein.
When Your Expression System Isn’t Cooperating With Your Protein
Strain Engineering & Process Development: A Commercially Proven Platform for Biopharmaceutical Manufacturing